Fitness criteria for Australian patients referred for chimeric antigen receptor T-cell therapy
Intern Med J
.
2022 Aug;52(8):1454-1456.
doi: 10.1111/imj.15868.
Authors
Constantine S Tam
1
2
3
4
,
P J Ho
4
5
,
Duncan Purtill
4
6
,
Emily Blyth
4
7
8
9
10
,
Jason Butler
4
11
,
Michael Dickinson
4
12
13
,
Simon Harrison
4
12
13
Affiliations
1
Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
2
Department of Haematology, Monash University, Melbourne, Victoria, Australia.
3
Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia.
4
National CAR-T Patient Prioritization Committee, Melbourne, Victoria, Australia.
5
Department of Haematology, Royal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia.
6
Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
7
Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales, Australia.
8
Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
9
Department of Haematology, Westmead Hospital, Sydney, New South Wales, Australia.
10
Institute for Medical Research, Sydney, New South Wales, Australia.
11
Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
12
Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
13
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
PMID:
35973961
DOI:
10.1111/imj.15868
No abstract available
Publication types
Letter
MeSH terms
Australia / epidemiology
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Receptors, Chimeric Antigen* / therapeutic use
T-Lymphocytes
Substances
Receptors, Chimeric Antigen